Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02772276 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
A Phase 2 study, sponsored by MediBeacon.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT02772276: Completed Phase 2 study, sponsored by MediBeacon.
NCT02772276 is a Phase 2 study that has completed, run by MediBeacon. The registered enrollment target is 234 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02772276, a Phase 2 study, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
Primary Outcome
An adverse event is defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, temporally associated with the use of a medicinal product, whether or not related to the investigational medical device or drug.
Interventions
- DRUG Iohexol
- DRUG MB-102-- single dose of 4 µmol/kg
- DRUG MB-102-- single dose of 130 mg
- DRUG MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart
- DRUG MB-102-- two doses of 130 mg 24 hours apart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2021-08-04 |
| Phase | Phase 2 |
What the finished NCT02772276 record still lists
NCT02772276 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% higher).
The record links to 0 conditions, and to 5 interventions - of which Iohexol is the first listed.
NCT02772276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02772276 about?
NCT02772276 is a clinical study titled "Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types". This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.
What is the current status of trial NCT02772276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2016-05-11. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT02772276?
The interventions under investigation include: Iohexol (DRUG), MB-102-- single dose of 4 µmol/kg (DRUG), MB-102-- single dose of 130 mg (DRUG), MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart (DRUG), MB-102-- two doses of 130 mg 24 hours apart (DRUG).
Who is sponsoring clinical trial NCT02772276?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02772276's enrollment target sits among peer trials
234 255th of 2000 higher than 1,745 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI